Trial Profile
A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tuberculosis vaccine (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Aeras
- 26 May 2015 Treatment lines amended; dosage in the groups were revised.
- 17 Apr 2014 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record
- 13 Nov 2012 Planned End Date changed from 1 Dec 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.